NEW YORK, Jan. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the upcoming JPMorgan 26th Annual Healthcare Conference, taking place in San Francisco. Mr. Weiss' presentation will take place on Tuesday, January 8th, at 9:00 am PT.
Mr. Weiss' presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of the webcast will be available approximately 24 hours following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965
E-mail: DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director - Investor Relations, Keryx Biopharmaceuticals, Inc., +1-212-531-5965, Web site: http://investors.keryx.com/
|